Board Change

Haleon plc: Board Change

25 February 2025: Haleon plc (the "Company" or "Haleon") (LSE/NYSE: HLN) today announces the following change to the Board.

Following the reduction of Pfizer Inc.'s shareholding in Haleon plc below 10%, and in line with the Pfizer Relationship Agreement with Haleon plc, Bryan Supran, Non-Executive Director and representative of Pfizer Inc., stepped down from the Board on 25 February 2025.

Sir Dave Lewis, Haleon's Chair commented: "On behalf of the Board, I would like to thank Bryan for his contributions to the Board's discussions and for being part of the Haleon journey from the initial joint-venture in 2019 through demerger to today. We wish him all the very best for the future."

The Company confirms that there is no further information to be disclosed under the requirements of UKLR 6.4.6R.

Amanda Mellor 

Company Secretary 

About Haleon

Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans five major categories - Oral Health, Pain Relief, Respiratory Health, Digestive Health and Other, and Vitamins, Minerals and Supplements (VMS). Its long-standing brands - such as Advil, Sensodyne, Panadol, Voltaren, Theraflu, Otrivin, Polident, parodontax and Centrum - are built on trusted science, innovation and deep human understanding.

For more information, please visit www.haleon.com.